BioNexus Gene Lab Corp is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in Kuala Lumpur, MY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $7 million and a loss of $3 million (its filed statements).
Usage businessServices-Medical LaboratoriesKuala Lumpur, MYfilings since 20198 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 2.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.7 out of ten, present 2.7 out of ten, future 2.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.9 out of ten. 16 warning events since 2019; the latest 2026-03-31. 9th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.7 out of ten. +66.2% a year over 8 filed years; profitable in 3 of 8. 47th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.8 out of ten. CrossAssetData estimate 5.8/10, confidence 20 of 100 (family median). 50th percentile among 20 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Financial health (present): 5.6 out of ten. ROE -35%: lost 35¢ per shareholder dollar. Leverage 7%: owes 7¢ per asset dollar. 56th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 1.8 out of ten. bottom 18% of 23 in its family; net margin -40.2%. 18th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 0.3 out of ten. bottom 3% of 17 in its family for leadership; chief executive since 2026. 3rd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.1 out of ten. bottom 31% of 23 in its family for room to expand. 31st percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 1.5 out of ten. bottom 15% of 23 in its family for growth drivers. 15th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 2.3 out of ten. bottom 23% of 20 in its family for expectations against reality. 23rd percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-04-14 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-14 for the period ended 2026-06-30 (on EDGAR). Newest filing: Form 8-K, 2026-10-07. Filings on record since 2019. Read from EDGAR 2026-10-12.
Where the revenue comes from
By geography: Malaysia 79%, Maldives 9%, Sri Lanka 6%, Singapore 3%, Indonesia 2%, Bangladesh 1%. As tagged in its annual report (Form 10-K, filed 2026-04-14).
Who runs it
Tan, Lee Su-Leng (Chief Executive Officer); Chong, Set Fui (Chief Financial Officer); Bin, Abdul Hamid Muhammad Azrul (director); Low, Jook Yuen (director); Yap, Chee Keong (director). 5 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.